Orum Therapeutics Announces Three Presentations At AACR 2023
Poster Title:
PD-1-Cbl-bi TPS² preclinical poster
A novel antibody-enabled Dual-precision Targeted Protein Stabilization (TPS²) that augments anti-tumor immune response by targeting Cbl-b inhibitor to exhausted T cells while blocking checkpoint molecule, PD-1
ORM-6151: A first-in-class CD33-antibody enabled GSPT1 degrader for AML
ORM-5029 predictive biomarker poster
Development of RNAscope multiplex-based assay for exploratory pharmacodynamic biomarkers assessment in breast cancer patients from Phase I clinical trial of ORM-5029, a potent GSPT1 degrader
Date and Time: 4/17/2023, 9:00 AM - 12:30 PM ET
Orum Therapeutics Presents Positive Preclinical Data Of ORM-6151 at ASH 2022
Title: ORM-6151, A First-In-Class, CD33-GSPT1 Dual-Precision Targeted Protein Degrader For AML.
Date and Time: 12/10/22 5:30 PM to 7:30 PM CST
Orum Therapeutics Presents Positive Preclinical Data Of ORM-6151, A First-In-Class, CD33-GSPT1 Dual-Precision Targeted Protein Degrader For AML, At ASH 2022
Poster Title: ORM-6151: A First-in-Class, Anti-CD33 Antibody-Enabled GSPT1 Degrader for AML
Date and Time: 12/10/2022, 5:30 PM to 7:30 PM CST
Orum Therapeutics Presents Preclinical Data At AACR 2022 Highlighting Novel Dual-Precision Targeted Protein Degrader, ORM-5029, Degrading GSPT1
Date and Time: 4/13/2022, 9:00 AM to 12:30 PM ET